The need for new anti-hepatitis C virus therapeutic strategies: Targeting the cellular micro-ribonucleic acids?

Sultan Qaboos University Medical Journal

Volumn 10, Issue 3, 2010, Pages 312-317

  Said, Elias A ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Hepatitis C virus; Infection; Interferon; Liver; MicroRNAs; Therapy

Indexed keywords

EID: 84870288172     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:S21-9.
2. Hepatitis C. Geneva: World Health Organization, 2002. pp. 1-69 (WHO/CDS/CSR/LYO/2003) From: http://www.who.int/csr/disease/hepatitis/Hepc.pdf. Accessed: March 2010.
3. Gish RG, Lau JYN. Hepatitis C virus: eight years old. Viral Hep Rev 1997; 3:17-37.
4. Maertens G, Stuyver L. Genotypes and genetic variation of Hepatitis C virus. In: Harrison TJ, Zuckerman AJ, Eds. The Molecular Medicine of Viral Hepatitis. Hoboken, NJ: Wiley, 1997. pp. 183-233.
5. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32:884-92.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
7. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105:7034-9.
8. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25:71-99.
9. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004; 58:391- 424.
10. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:5550-8.
11. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004; 78:13779-92.
12. Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology 2007; 46:999-1008.
13. Zeuzem S, Poordad F. Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response. Curr Med Res Opin 2010; 26:1733-43.
14. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
15. HCV Experimental Treatments HIV and Hepatitis Treatment Advocates, Inc. From: http://www. hivandhepatitis.com/hep_c/hepc_news_alter.html. Accessed: Sept 2010.
16. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65:202- 12.
17. UK Collaborative Group on HIV Drug Resistance. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 2010; 50:1286-7.
18. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-22.
19. Lihana RW, Khamadi SA, Lubano K, Lwembe R, Kiptoo MK, Lagat N, et al. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy. AIDS Res Hum Retroviruses 2009; 25:1211-7.
20. Fluiter K, Mook OR, Baas F. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence. Methods Mol Biol 2009; 487:189-03.
21. Niepmann M. Activation of hepatitis C virus translation by a liver-specific microRNA. Cell Cycle 2009; 8:1473-7.
22. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010; 84:6615- 25.
23. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449; 919-22.
24. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15:31-3.
25. Ye L, Wang X, Wang S, Wang Y, Song L, Hou W, et al. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatology 2009; 49:753-62.
26. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198-201.
27. Young DD, Connelly CM, Grohmann C, Deiters A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 2010; 132:7976-81.
28. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010; 51:1494- 504.
29. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009; 50:453-60.